If You Hold This Healthcare ETF, You're Losing Big

FHLC is down about 5% year to date and has returned just 15% over five years versus roughly 80% for the S&P 500, highlighting persistent sector underperformance. The ETF charges a low 0.08% fee and yields well under 2%, but the article argues that low-cost underperformance is still underperformance given its heavy concentration, including Eli Lilly at over 12% of assets. The piece recommends biotech or more targeted healthcare exposure over broad healthcare sector beta.

Analysis

The key issue is not just that broad healthcare is lagging; it’s that passive healthcare exposure is increasingly a disguised mega-cap pharma/managed-care factor bet. That matters because the sector’s upside is now being driven by a few idiosyncratic winners, while the rest of the basket behaves like a low-volatility defensive sleeve with limited multiple expansion. In other words, the ETF is structurally set up to miss the very places where healthcare alpha has been clustering: innovation-heavy biotech, reimbursement-sensitive services, and niche operators with operating leverage.

LLY is the pressure point inside the basket. A single-name drawdown there would not only hit the fund mechanically, it would likely de-rate the entire healthcare complex because passive flows have concentrated benchmarking around the same few names. The second-order effect is that any disappointment in GLP-1 adoption, pricing, or competition could cause a rotation out of “quality healthcare” and into deeper value corners of the sector rather than a clean sector-wide selloff. That creates relative-value opportunities versus the ETF, not just outright bearishness.

The contrarian read is that the underperformance may be closer to a sentiment/regime problem than a permanent fundamental impairment. If rates fall and defensives regain favor, healthcare could re-rate quickly because expectations are already low and positioning is likely light. But the timing matters: this is more of a 6-18 month catalyst window than a 1-2 quarter trade, unless there is a specific catalyst in LLY or drug-pricing policy.

The highest-conviction implication is that “everything healthcare” is the wrong vehicle if the goal is upside participation. Investors want to separate cash-generative defensive pharma from true growth and from operationally sensitive subsectors; bundling them together suppresses both upside capture and risk control. The better trades are relative-value expressions and selective exposure, not passive beta.

Key Decisions for Investors

• Underweight FHLC versus XLV over the next 3-6 months; same defensive exposure, but better liquidity and a cleaner benchmark fit. Risk/reward favors the larger fund if you need sector beta, while FHLC’s smaller base makes it more vulnerable to single-name concentration shocks.
• Pair trade: long XBI / short FHLC for a 6-12 month horizon. The thesis is that innovation-driven biotech has more convexity and less benchmark drag than a cap-weighted healthcare basket; stop if biotech financing conditions tighten materially or risk appetite rolls over.
• If holding FHLC, cap exposure at 3%-5% of portfolio NAV and fund it from a cyclical or broad-market sleeve. This keeps healthcare as a hedge rather than a return driver; upside is limited, but drawdown control improves if pharma multiples compress.
• For event-driven traders, use LLY weakness as the trigger rather than the ETF itself: buy 3-6 month put spreads on FHLC if LLY breaks technical support on volume. The ETF will likely transmit single-name pain with less idiosyncratic recovery than owning the stock directly.
• Add targeted exposure to healthcare subsectors with operating leverage outside mega-cap pharma instead of the ETF wrapper. Better risk/reward exists in niche services and biotech where fundamentals can still expand multiples over 6-18 months.